Home > Healthcare > Drug Device Combination > Therapeutic Systems > Oncolytic Virus Immunotherapy Market

Oncolytic Virus Immunotherapy Market Analysis

  • Report ID: GMI8770
  • Published Date: Mar 2024
  • Report Format: PDF

Oncolytic Virus Immunotherapy Market Analysis

Based on the virus type, the market is classified into herpes simplex virus (HSV), adenovirus, vaccinia virus, Newcastle disease virus, reovirus, and other virus types. The HSV segment has asserted its dominance in the global market by securing a significant share and experiencing growth of 22.7% between 2024 – 2032.


  • The inherent properties of HSV have positioned it as a highly effective candidate for cancer immunotherapy demonstrating oncolytic capabilities by specifically infecting and replicating within cancer cells while leaving healthy tissue unaffected.


  • Furthermore, genetic modifications can enhance HSV's tumor-targeting and immune-stimulating capabilities. With its versatility, safety, and proven efficacy in preclinical and clinical studies, HSV stands as a leading oncolytic virus in immunotherapy, consolidating its dominance in cancer treatments.


Oncolytic Virus Immunotherapy Market, By Route of Administration (2023)

Based on the route of administration, the oncolytic virus immunotherapy market is classified into intratumoral, intravenous, and other routes of administration. The intravenous segment held the largest business share of 53% in 2023.


  • Intravenous administration of oncolytic viruses represents a highly effective approach for treating metastatic cancers. The delivery ensures superior systemic bioavailability, enabling targeted distribution to potential metastatic sites throughout the body in comparison to the intratumoral route. This maximizes the reach of oncolytic viruses, enhancing their ability to combat disseminated cancer cells and metastases.


  • Thus, intravenous administration stands out as a preferred method for delivering oncolytic viruses in the treatment of metastatic cancers, offering broader therapeutic coverage and potential clinical benefits.


Based on the application, the global oncolytic virus immunotherapy market is categorized into melanoma, breast cancer, lung cancer, ovarian cancer, prostate cancer, and other applications. The melanoma segment is expected to reach USD 713.5 million by 2032.


  • Melanoma holds unique characteristics that make it particularly susceptible to oncolytic virus therapy, such as a high mutation burden and an immunogenic tumor microenvironment. Melanoma of the skin ranks as the 17th most prevalent cancer globally. In the U.S., the American Cancer Society projects approximately 100,640 new cases of melanoma to be diagnosed in 2024. This has anticipated the need for effective melanoma treatment.


  • Additionally, the success of oncolytic viruses like Talimogene laherparepvec (T-VEC) in clinical trials for melanoma treatment has garnered significant attention and adoption.


  • Furthermore, the limited efficacy of conventional therapies in advanced melanoma patients has created a strong demand for innovative treatment options, thereby driving the prominence of oncolytic virus immunotherapy in melanoma management.


Based on the end-user, the oncolytic virus immunotherapy market is classified into hospitals & clinics, cancer research institutes, ambulatory surgical centers, and other end-users. The hospitals & clinics segment accounted for 39.1% market share in 2023 and is expected to reach USD 735.1 million by 2032.


  • Hospitals play a central role in serving as primary treatment centers for cancer patients. Availability of advanced facilities and specialized oncology departments, the hospitals facilitate the administration of oncolytic virus therapies, including diagnosis, treatment planning, and patient care.


  • Their multidisciplinary approach, access to cutting-edge technologies, and collaboration with research institutions enable hospital & clinics to lead advancements in oncolytic virus immunotherapy, making them pivotal segment in the market.


North America Oncolytic Virus Immunotherapy Market, 2021 – 2032 (USD Million)

North America region is projected to maintain its lead in the global oncolytic virus immunotherapy market, anticipated to exhibit 22.3% CAGR during the analysis period.


  • North America is poised to maintain a significant dominance due to its growing patient population and rising cancer incidences. According to the American Cancer Society's 2021 report, the U.S. recorded approximately 1.9 million new cancer cases and 608,570 deaths in 2021.


  • Similarly, according to the Centers for Medicare and Medicaid Services (CMS), increasing awareness of cancer treatments, the availability of advanced immune-oncology therapies, and rising healthcare spending reached nearly USD 4.1 trillion in 2020. Thus, rising healthcare expenditure, presence of key players in the region along with growing awareness pertaining to early diagnosis and treatment is expected to contribute to the market progress.
Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

Oncolytic virus immunotherapy market size was USD 302.6 million in 2023 and is expected to register 22.6% CAGR from 2024-2032 owing to the increasing incidence of cancer worldwide, which necessitated the development of novel and effective treatment options.

The herpes simplex virus (HSV) segment is expected to register 22.7% CAGR from 2024-2032 due to its ability to specifically infect and replicate within cancer cells while leaving healthy tissue unaffected.

North America oncolytic virus immunotherapy industry is expected to register 22.3% CAGR from 2024-2032 due to the growing patient population and rising cancer incidences in the region.

Amgen Inc., Creative Biolabs, Daiichi Sankyo Company Limited, Genelux Corporation, Oncorus Inc., Replimune Inc., Siga Technologies, Sorrento Therapeutics Inc., TILT Biotherapeutics, and Viralytics Ltd., are some of the major oncolytic virus immunotherapy companies worldwide.

Oncolytic Virus Immunotherapy Market Scope

Buy Now

Premium Report Details

  • Base Year: 2023
  • Companies covered: 12
  • Tables & Figures: 295
  • Countries covered: 19
  • Pages: 160
 Download Free Sample